| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Kira Griffiths, Maria Ruiz Mellado, Raymond Chung, John Lally, Grant McQueen, Kyra-Verena Sendt, Amy Gillespie, Muhammad Ibrahim, Alex Richter, Adrian Shields, Mark Ponsford, Stephen Jolles, John Hodsoll, Thomas Pollak, Rachel Upthegrove, Alice Egerton, James H MacCab. Changes in immunoglobulin levels during clozapine treatment in schizophrenia. Brain, behavior, and immunity. 2023-10-13. PMID:37832895. |
changes in immunoglobulin levels during clozapine treatment in schizophrenia. |
2023-10-13 |
2023-10-15 |
Not clear |
| Kira Griffiths, Maria Ruiz Mellado, Raymond Chung, John Lally, Grant McQueen, Kyra-Verena Sendt, Amy Gillespie, Muhammad Ibrahim, Alex Richter, Adrian Shields, Mark Ponsford, Stephen Jolles, John Hodsoll, Thomas Pollak, Rachel Upthegrove, Alice Egerton, James H MacCab. Changes in immunoglobulin levels during clozapine treatment in schizophrenia. Brain, behavior, and immunity. 2023-10-13. PMID:37832895. |
use of clozapine in treatment-resistant schizophrenia is often limited due to risk of adverse effects. |
2023-10-13 |
2023-10-15 |
Not clear |
| Zixu Yang, Hiroyoshi Takeuchi, Jie Yin Yee, Yuen Mei See, Charmaine Tang, Boon Tat Ng, Jimmy Le. Once-daily versus divided dosing regimens of clozapine: A cross-sectional study in Singapore. Schizophrenia research. 2023-10-13. PMID:37833207. |
clozapine is recognized as the gold standard medication for treatment-resistant schizophrenia. |
2023-10-13 |
2023-10-15 |
Not clear |
| Isabella Berardelli, Mariarosaria Cifrodelli, Carlotta Giuliani, Giulia Antonelli, Carolina Putotto, Federica Pulvirenti, Maurizio Pompil. Efficacy and safety of clozapine in treatment-resistant psychotic patients with DiGeorge syndrome (22q11.2 deletion syndrome): a case series. International clinical psychopharmacology. 2023-10-12. PMID:37824335. |
furthermore, in our patients, the clinical effectiveness was achieved with a very low dose of clozapine (<150 mg/day) concerning the standard dose used in idiopathic schizophrenia (>300 mg/day to 600 mg/day). |
2023-10-12 |
2023-10-15 |
Not clear |
| Francesco Franza, Annalisa Soddu, Nicoletta Fiorentino, Luigi Calabrese, Albino Zarrella, Barbara Solomita, Giuseppe Tavormin. The Interference of Negative Symptoms of Schizophrenia on Cognitive Domains: a Long-Term Observational Study on the Role of Clozapine. Psychiatria Danubina. vol 35. issue Suppl 2. 2023-10-06. PMID:37800215. |
the interference of negative symptoms of schizophrenia on cognitive domains: a long-term observational study on the role of clozapine. |
2023-10-06 |
2023-10-07 |
Not clear |
| Francesco Franza, Annalisa Soddu, Nicoletta Fiorentino, Luigi Calabrese, Albino Zarrella, Barbara Solomita, Giuseppe Tavormin. The Interference of Negative Symptoms of Schizophrenia on Cognitive Domains: a Long-Term Observational Study on the Role of Clozapine. Psychiatria Danubina. vol 35. issue Suppl 2. 2023-10-06. PMID:37800215. |
our small 5-year observational study evaluated the efficacy of clozapine in negative and cognitive symptoms in schizophrenia inpatients. |
2023-10-06 |
2023-10-07 |
Not clear |
| Natalie Kwok Wing Cheuk, Wing Tse, Harry Kam Hung Tsui, Chak Fai Ma, Johnny Siu Wah Chun, Albert Kar Kin Chung, Sherry Kit Wa Cha. A systematic review and meta-analysis of the effect of clozapine on cognitive functions in patients with treatment-resistant schizophrenia. Schizophrenia research. 2023-10-03. PMID:37788946. |
a systematic review and meta-analysis of the effect of clozapine on cognitive functions in patients with treatment-resistant schizophrenia. |
2023-10-03 |
2023-10-07 |
Not clear |
| Natalie Kwok Wing Cheuk, Wing Tse, Harry Kam Hung Tsui, Chak Fai Ma, Johnny Siu Wah Chun, Albert Kar Kin Chung, Sherry Kit Wa Cha. A systematic review and meta-analysis of the effect of clozapine on cognitive functions in patients with treatment-resistant schizophrenia. Schizophrenia research. 2023-10-03. PMID:37788946. |
this study aimed to conduct a systematic review and meta-analysis on cognitive performances of patients with treatment-resistant schizophrenia (trs) after clozapine treatment and to examine the potential effect of follow-up duration and clozapine dosage. |
2023-10-03 |
2023-10-07 |
Not clear |
| Botao Ma, Hongzhen Fan, Siyuan Qi, Fude Yang, Huimei A. Effects of smoking cessation on plasma clozapine concentrations in male patients with schizophrenia during the COVID-19 pandemic. Frontiers in psychiatry. vol 14. 2023-10-02. PMID:37779619. |
effects of smoking cessation on plasma clozapine concentrations in male patients with schizophrenia during the covid-19 pandemic. |
2023-10-02 |
2023-10-07 |
Not clear |
| Botao Ma, Hongzhen Fan, Siyuan Qi, Fude Yang, Huimei A. Effects of smoking cessation on plasma clozapine concentrations in male patients with schizophrenia during the COVID-19 pandemic. Frontiers in psychiatry. vol 14. 2023-10-02. PMID:37779619. |
this study aimed to investigate the effect of smoking cessation on plasma clozapine (clo) concentrations in long-term hospitalized chinese male patients with schizophrenia treated with clo during the covid-19 pandemic. |
2023-10-02 |
2023-10-07 |
Not clear |
| Kouji Fukuyama, Eishi Motomura, Motohiro Okad. A Novel Gliotransmitter, L-β-Aminoisobutyric Acid, Contributes to Pathophysiology of Clinical Efficacies and Adverse Reactions of Clozapine. Biomolecules. vol 13. issue 9. 2023-09-28. PMID:37759688. |
clozapine is listed as one of the most effective antipsychotics and has been approved for treating treatment-resistant schizophrenia (trs); however, several type a and b adverse reactions, including weight gain, metabolic complications, cardiotoxicity, convulsions, and discontinuation syndromes, exist. |
2023-09-28 |
2023-10-07 |
Not clear |
| Kouji Fukuyama, Eishi Motomura, Motohiro Okad. A Novel Gliotransmitter, L-β-Aminoisobutyric Acid, Contributes to Pathophysiology of Clinical Efficacies and Adverse Reactions of Clozapine. Biomolecules. vol 13. issue 9. 2023-09-28. PMID:37759688. |
considering the expressions of gaba-b and iii-mglu receptors (localised in the presynaptic regions), the activation of gaba-b and iii-mglu receptors can explain the distinct therapeutic advantages of clozapine in schizophrenia or trs associated with n-methyl-d-aspartate (nmda) receptor disturbance compared with other atypical antipsychotics via the inhibition of the persistent tonic hyperactivation of thalamocortical glutamatergic transmission in the prefrontal cortex. |
2023-09-28 |
2023-10-07 |
Not clear |
| Anoop Sankaranarayanan, Sharmin Kazi, Chittaranjan Andrad. Prevalence and predictors of QTc prolongation in patients seen in a clozapine clinic in a real-world setting in Australia. Schizophrenia research. 2023-09-28. PMID:37770378. |
we studied the prevalence and predictors of qtc prolongation in treatment-resistant schizophrenia patients who were receiving clozapine in a real-world setting. |
2023-09-28 |
2023-10-07 |
Not clear |
| Nuree Kang, Se Hyun Kim, Jayoun Kim, Sungkyu Kim, Jinhyeok Jang, Heesoo Yoon, Jeonghoon Lee, Minah Kim, Yong Sik Kim, Jun Soo Kwo. Association between initial clozapine titration and pneumonia risk among patients with schizophrenia in a Korean tertiary hospital. Schizophrenia research. 2023-09-28. PMID:37770376. |
association between initial clozapine titration and pneumonia risk among patients with schizophrenia in a korean tertiary hospital. |
2023-09-28 |
2023-10-07 |
Not clear |
| Thanompong Sathienluckana, Thaksin Jansing, Supakan Srisuriyakamon, Aunchalee Thonkhunthod, Parsiri Sangsuwanto, Pholphat Losatiankij, Suttha Supany. Comparison of the Effectiveness and Safety of Clozapine Between Once-Daily and Divided Dosing Regimen in Patients With Treatment-Resistant Schizophrenia. The Annals of pharmacotherapy. 2023-09-25. PMID:37743679. |
comparison of the effectiveness and safety of clozapine between once-daily and divided dosing regimen in patients with treatment-resistant schizophrenia. |
2023-09-25 |
2023-10-07 |
Not clear |
| Thanompong Sathienluckana, Thaksin Jansing, Supakan Srisuriyakamon, Aunchalee Thonkhunthod, Parsiri Sangsuwanto, Pholphat Losatiankij, Suttha Supany. Comparison of the Effectiveness and Safety of Clozapine Between Once-Daily and Divided Dosing Regimen in Patients With Treatment-Resistant Schizophrenia. The Annals of pharmacotherapy. 2023-09-25. PMID:37743679. |
clozapine is the most effective antipsychotic with respect to the incidence of discontinuation and is indicated for treatment-resistant schizophrenia. |
2023-09-25 |
2023-10-07 |
Not clear |
| Feiyan Yin, Zhidao Shi, Xiquan Ma, Kai Ding, Yuan Zhang, Sha M. Impact of clozapine monotherapy on gut microbiota and metabolism in people with schizophrenia. Frontiers in microbiology. vol 14. 2023-09-25. PMID:37744899. |
impact of clozapine monotherapy on gut microbiota and metabolism in people with schizophrenia. |
2023-09-25 |
2023-10-07 |
Not clear |
| Gamze Gürcan, Şevin Hun Şenol, A Elif Anıl Yağcıoğlu, Aygün Ertuğru. Effect of clozapine on suicidality in patients with schizophrenia at a university hospital in Turkey. Schizophrenia research. 2023-09-21. PMID:37735049. |
effect of clozapine on suicidality in patients with schizophrenia at a university hospital in turkey. |
2023-09-21 |
2023-10-07 |
Not clear |
| Edouard-Jules Laforgue, Marion Istvan, Anicet Chaslerie, Pascal Artarit, Geneviève Vallot, Pascale Jolliet, Marie Grall-Bronnec, Caroline Victorri-Vignea. Characterization of antipsychotic utilization before clozapine initiation for individuals with schizophrenia: an innovative visualization of trajectories using French National Health Insurance data. Epidemiology and psychiatric sciences. vol 32. 2023-09-19. PMID:37723967. |
characterization of antipsychotic utilization before clozapine initiation for individuals with schizophrenia: an innovative visualization of trajectories using french national health insurance data. |
2023-09-19 |
2023-10-07 |
Not clear |
| Masakazu Hatano, Hiroyuki Kamei, Ippei Takeuchi, Kazuhiko Gomi, Takashi Sakakibara, Shogo Hotta, Satoru Esumi, Kiyotaka Tsubouchi, Yoshihito Shimizu, Shigeki Yamad. Long-term outcomes of delayed clozapine initiation in treatment-resistant schizophrenia: a multicenter retrospective cohort study. BMC psychiatry. vol 23. issue 1. 2023-09-15. PMID:37715155. |
long-term outcomes of delayed clozapine initiation in treatment-resistant schizophrenia: a multicenter retrospective cohort study. |
2023-09-15 |
2023-10-07 |
Not clear |